Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Congenital Abnormalities 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

fludarabine phosphate 73Peripheral Blood Stem Cell Transplantation 63Cyclophosphamide 59Busulfan 51Tacrolimus 46Mycophenolic Acid 46Cytarabine 44Whole-Body Irradiation 41Cyclosporine 37Methotrexate 34Antilymphocyte Serum 33Filgrastim 30Etoposide 29Radiotherapy 22Melphalan 21Flow Cytometry 21Cord Blood Stem Cell Transplantation 17Mitoxantrone 14Methylprednisolone 14Transplantation 13Granulocyte Colony-Stimulating Factor 12Idarubicin 11Clofarabine 11sargramostim 10aldesleukin 10Thiotepa 9Polymerase Chain Reaction 9Alemtuzumab 9merphos 8Therapeutics 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Congenital Abnormalities × trebananib × Clear all
NCT01555268 2022-09-13

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Completed
24 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡